As Director, Medical Science Liaison, Phase I/II, at Altasciences, Gregory Reid is currently assisting drug developers in formulating and executing strategies around FIH and NDA-enabling clinical studies.
Early development clinical trials for CNS drugs are complex and can require in-depth clinical expertise. When conducting CNS trials, it is critical that contract research organizations implement thorough processes in areas such as volunteer eligibility and operational conduct.
Altasciences is a leader in the field of early phase clinical conduct for CNS trials. Our Principal Investigators, Clinicians, Technical Staff, Nurses, and Management Team have an extensive understanding of psychiatric and neurologic disorders stemming from our fifteen-year history of conducting complex studies in various therapeutic indications within CNS.
Click below to ask Greg a question.